Bloomberg Talks Teva CEO Talks Drug Pricing, Generics, Supply Shortages
4 snips
Jan 13, 2025 Teva Pharmaceuticals' CEO Richard Francis shares insights on the company's remarkable growth and its strategies for the future. He discusses the pressing issues of drug pricing and the challenges within the generics market. The conversation highlights supply shortages of Adderall, balancing production with demand. Additionally, the discussion touches on the exciting development of GLP-1 generics and the implications for healthcare mergers and acquisitions, emphasizing the need for strong capital management and innovative practices.
AI Snips
Chapters
Transcript
Episode notes
Teva's Share Performance
- Teva Pharmaceuticals saw its shares rise 11%
- This success is attributed to strong performance of innovative products and a maturing pipeline.
Generic Drug Pricing
- Generic drug prices continue to decline, impacting the generics business.
- Teva, a major generics supplier, emphasizes the need for fair pricing within healthcare systems.
Adderall Shortage
- Adderall shortages persist due to increased prescriptions and government quotas on manufacturing.
- Richard Francis suggests investigating overprescribing as a contributing factor.